Automated detection of neutropenia using non‐invasive video microscopy of superficial capillaries

TY - JOUR

T1 - Automated detection of neutropenia using non‐invasive video microscopy of superficial capillaries

AU - Pablo-Trinidad, Alberto

AU - Butterworth, Ian

AU - Ledesma‐Carbayo, María J.

AU - Vettenburg, Tom

AU - Sánchez‐Ferro, Álvaro

AU - Soenksen, Luis

AU - Durr, Nicholas J.

AU - Muñoz Barrutia, Arrate

AU - Cerrato, Carolina

AU - Humala, Karem

AU - Fabra Urdiol, Marta

AU - Del Rio, Candice

AU - Valles, Betsy

AU - Chen, Yi‐Bin

AU - Hochberg, Ephraim P.

AU - Castro‐González, Carlos

AU - Bourquard, Aurélien

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Cancer patients undergoing cytotoxic chemotherapy are at elevated risk of developing serious infections. The risk of developing these infections increases when white blood cell (WBC) count, particularly the absolute neutrophil counts (ANC), are reduced. This reduction in neutrophil counts, the most abundant white-blood-cell subtype, is referred to as neutropenia, with these infection episodes termed febrile neutropenia (FN). Patients have a high risk of developing FN during sustained severe neutropenia (ANC<500/μL), which is a common side effect of cytotoxic chemotherapies. FN occurs frequently, currently in approximately one in six of all chemotherapy patients, and it is associated with a high rate of mortality, where 11% of patients die after one or several hospitalizations. In the US alone, the associated cost due to such hospitalizations accounts for $2.7B dollars annually, contributing to up to 40% of the total cost of cancer treatments.

AB - Cancer patients undergoing cytotoxic chemotherapy are at elevated risk of developing serious infections. The risk of developing these infections increases when white blood cell (WBC) count, particularly the absolute neutrophil counts (ANC), are reduced. This reduction in neutrophil counts, the most abundant white-blood-cell subtype, is referred to as neutropenia, with these infection episodes termed febrile neutropenia (FN). Patients have a high risk of developing FN during sustained severe neutropenia (ANC<500/μL), which is a common side effect of cytotoxic chemotherapies. FN occurs frequently, currently in approximately one in six of all chemotherapy patients, and it is associated with a high rate of mortality, where 11% of patients die after one or several hospitalizations. In the US alone, the associated cost due to such hospitalizations accounts for $2.7B dollars annually, contributing to up to 40% of the total cost of cancer treatments.

UR - https://www.scopus.com/pages/publications/85067409963

UR - https://discovery.dundee.ac.uk/en/publications/3da34cac-2eb5-481a-a181-507356614c15

U2 - 10.1002/ajh.25516

DO - 10.1002/ajh.25516

M3 - Letter

C2 - 31120579

SN - 0361-8609

VL - 94

SP - E219-E222

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 8

ER -